Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.05. | Aardvark Therapeutics strukturiert Führungsteam während Phase-3-Studie um | 2 | Investing.com Deutsch | ||
19.05. | Aardvark Therapeutics reshuffles leadership amid Phase 3 study | 2 | Investing.com | ||
19.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions | 62 | GlobeNewswire (Europe) | Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian... ► Artikel lesen | |
15.05. | Aardvark Therapeutics reports Q1 results | 2 | Seeking Alpha | ||
14.05. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights | 76 | GlobeNewswire (Europe) | Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term... ► Artikel lesen | |
01.04. | RBC Capital maintains $21 target on Aardvark Therapeutics stock | 1 | Investing.com | ||
01.04. | Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock | 1 | Investing.com | ||
31.03. | Aardvark Therapeutics, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
31.03. | Aardvark Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights | 42 | GlobeNewswire (Europe) | Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to... ► Artikel lesen | |
27.03. | BofA lifts Aardvark Therapeutics target to $26, maintains Buy | 2 | Investing.com | ||
10.03. | RBC Capital sets Aardvark Therapeutics at Outperform | 1 | Investing.com | ||
10.03. | BofA sets Aardvark Therapeutics stock with $22 target | 3 | Investing.com | ||
14.02. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.02. | Aardvark Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
13.02. | Aardvark Therapeutics prices $94.2m IPO to fund development of Prader-Willi syndrome drug | 1 | Pharmaceutical Technology | ||
13.02. | Aardvark Therapeutics' Pursuit of New Obesity Target Adds $94M in IPO Cash | 2 | MedCity News | ||
13.02. | Metabolic disease biotech Aardvark Therapeutics prices IPO at $16, the low end of the range | 2 | Renaissance Capital | ||
13.02. | Aardvark Therapeutics heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials | 2 | FierceBiotech |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
BIONTECH | 99,15 | +1,69 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
QIAGEN | 40,320 | -0,01 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |